# US 2025/0084144 A1 · Dual-target fusion proteins comprising fgf21 and glp-1, connected through a fc portion of an immunoglobulin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084144 A1
- Document ID: US20250084144A1
- Status: Published application
- Kind: A1
- Application number: 18/805,686
- Filed: 2024-08-15
- Published: 2025-03-13
- Earliest claimed: 2017-03-14
- Assignees: Sunshine Lake Pharma Co., Ltd.
- Applicants: Sunshine Lake Pharma Co., Ltd.
- Inventors: Chao CHEN; Shushan LIN; Yu LI; Xiaofeng CHEN; Liang LIU; Zheng FU
- Web page: https://patentgrep.com/patent/US20250084144A1

## CPC

- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C07K 14/605: Glucagons
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/50: Fibroblast growth factor [FGF]
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided is a fusion protein containing GLP-1 and FGF21 linked through an immunoglobulin Fc portion. Each of the GLP-1 and FGF21 can be substituted with its analogues or variants and, the Fc portion, which can be derived from IgG4, can include substitutions that further enhance the fusion protein's stability and activity. These fragments can be linked together through peptide linkers. The fusion protein can be used clinically to reduce glucose and lipid levels and body weight.

## Claims

### Claim 1

A fusion protein comprising or consisting of:
a) a first polypeptide, wherein the first polypeptide is glucagon-like peptide-1 (GLP-1) or an analogue thereof;
b) a second polypeptide, wherein the second polypeptide is an IgG4 Fc portion comprising the amino acid sequence of SEQ ID NO: 2, or a variant thereof; and
c) a third polypeptide, wherein the third polypeptide is fibroblast growth factor 21 (FGF21) comprises the amino acid sequence of SEQ ID NO: 6 or a variant thereof,
wherein the first polypeptide is linked to the second polypeptide via a first linker and the third polypeptide is linked to the second polypeptide via a second linker; and
wherein the variant of SEQ ID NO: 6 comprises one or more mutations at positions including 167, 175 and 179; wherein the amino acid mutation at position 167 is selected from the group consisting of S167H and S167C; wherein the amino acid mutation at position 175 is selected from the group consisting of R175L, R175H and R175P; and wherein the amino acid mutation at position 179 is selected from the group consisting of Y179S and Y179F.

### Claim 2 (depends on 1)

The fusion protein of claim 1, wherein the GLP-1 analogue comprises or consists of the amino acid sequence of SEQ ID NO: 7
(HX1EGTFTSDVSSYLEX2QAAKEFIAWLX3X4GX5X6),
wherein X1 is selected from G or V;
X2 is selected from E or G;
X3 is selected from V or K;
X4 is selected from K or N;
X5 is selected from G or E; and
X6 is selected from G, P or absent.

### Claim 3 (depends on 1)

The fusion protein of claim 1, wherein the GLP-1 analogue comprises or consists of the amino acid sequence of SEQ ID NO: 1.

### Claim 4 (depends on 1)

The fusion protein of claim 1, wherein the FGF21 variant further comprises at least one amino acid mutation at position 170 or 172, wherein
the amino acid mutation at position 170 is selected from the group consisting of G170E, G170A, G170C, G170D, G170N, and G170S; and
the amino acid mutation at position 172 is selected from the group consisting of S172L, S1721, S172V, S172A, and S172M.

### Claim 5 (depends on 4)

The fusion protein of claim 4, wherein the FGF21 variant comprises at least one amino acid mutation at position 170 or 172, wherein
the amino acid mutation at position 170 is selected from the group consisting of G170E, G170A, G170D, and G170S; and
the amino acid mutation at position 172 is selected from the group consisting of S172L, S172V, and S172M.

### Claim 6 (depends on 4)

The fusion protein of claim 4, wherein the FGF21 variant comprises at least one amino acid mutation at position 170 or 172, wherein
the amino acid mutation at position 170 is selected from the group consisting of G170E, and G170A; and
the amino acid mutation at position 172 is S172L.

### Claim 7 (depends on 1)

The fusion protein of claim 1, wherein the FGF21 variant further comprises one or more mutations at one or more sites selected from the group consisting of 45, 100, 150, 151, 152, and 180; wherein
the amino acid mutation at position 45 is selected from the group consisting of A45K, A45R, A45E, and A45Q;
the amino acid mutation at position 100 is LIO0K;
the amino acid mutation at position 150 is P150A;
the amino acid mutation at position 151 is G151A;
the amino acid mutation at position 152 is I152V; and
the amino acid mutation at position 180 is selected from the group consisting of A180S, A180E, and A180G.

### Claim 8 (depends on 1)

The fusion protein of claim 1, wherein the FGF21 variant further comprises one or more mutations at one or more sites selected the group consisting of 45 and 180,
wherein the amino acid mutation at position 45 is selected from the group consisting of A45K, A45R, A45E, and A45Q; and the amino acid mutation at position 180 is selected from the group consisting of A180S, A180E, and A180G.

### Claim 9 (depends on 1)

The fusion protein of claim 1, wherein the amino acid mutation at position 167 of the FGF21 variant is S167H; the amino acid mutation at position 175 of the FGF21 variant is R175L; and the amino acid mutation at position 179 of the FGF21 variant is Y179F.

### Claim 10 (depends on 1)

The fusion protein of claim 1, wherein the first linker and the second linker each independently comprises a polypeptide of 5 to 50 amino acid residues, and the polypeptide comprises at least 50% G.

### Claim 11 (depends on 1)

The fusion protein of claim 1, wherein the first linker and the second linker each independently comprises a G-rich polypeptide comprising at least 50% G.

### Claim 12 (depends on 1)

The fusion protein of claim 1, wherein the first linker and the second linker each independently is selected from the amino acid sequence of SEQ ID NO: 32 (GGGGSGGGGS), or SEQ ID NO: 13 (GGGGSGGGGSGGGGS), or SEQ ID NO: 33 (GGGGSGGGGSGGGGSA).

### Claim 13 (depends on 1)

The fusion protein of claim 1, wherein the fusion protein is a homodimeric fusion protein or a non-homodimeric fusion protein.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the fusion protein of claim 1, and optionally one or more pharmaceutically acceptable adjuvants.

### Claim 15 (depends on 1)

A method of treating a metabolic disease in a patient comprising administrating a therapeutically effective amount of the fusion protein of claim 1 to the patient, wherein the metabolic disease is diabetes or hepatic steatosis.

### Claim 16

A fusion protein comprising or consisting of:
a) a first polypeptide, wherein the first polypeptide is glucagon-like peptide-1 (GLP-1) or an analogue thereof;
b) a second polypeptide, wherein the second polypeptide is an IgG4 Fe portion comprising the amino acid sequence of SEQ ID NO: 2 or a variant thereof; and
c) a third polypeptide, wherein the third polypeptide is fibroblast growth factor 21 (FGF21) comprising a variant of the amino acid sequence of SEQ ID NO: 15,
wherein the first polypeptide is linked to the second polypeptide via a first linker and the third polypeptide is linked to the second polypeptide via a second linker; and
wherein the variant of SEQ ID NO: 15 comprises one or more amino acid mutations at positions 98 and 171; wherein the amino acid mutation at position 98 is selected from the group consisting of L98D and L98R; and wherein the amino acid mutation at position 171 is selected from the group consisting of P171A and P171G; and
wherein the variant of SEQ ID NO: 15 further comprises one or more mutations at positions including 167, 175 and 179; wherein the amino acid mutation at position 167 is selected from the group consisting of S167H and S167C; wherein the amino acid mutation at position 175 is selected from the group consisting of R175L, R175H and R175P; and wherein the amino acid mutation at position 179 is selected from the group consisting of Y179S and Y179F.

### Claim 17 (depends on 16)

A pharmaceutical composition comprising the fusion protein of claim 16, and optionally one or more pharmaceutically acceptable adjuvants.

### Claim 18 (depends on 16)

A method of treating a metabolic disease in a patient comprising administrating a therapeutically effective amount of the fusion protein of claim 16 to the patient, wherein the metabolic disease is diabetes or hepatic steatosis.
